GI Innovation Inc
KOSDAQ:358570
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
8 970
24 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
GI Innovation Inc
Total Receivables
GI Innovation Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GI Innovation Inc
KOSDAQ:358570
|
Total Receivables
₩2B
|
CAGR 3-Years
107%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Total Receivables
₩975.7B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
3%
|
CAGR 10-Years
8%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Total Receivables
₩22.3B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Total Receivables
₩46.4B
|
CAGR 3-Years
18%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Total Receivables
₩53.9B
|
CAGR 3-Years
23%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Receivables
₩7.8B
|
CAGR 3-Years
11%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
GI Innovation Inc
Glance View
GI Innovation, Inc. engages in the development of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 88 full-time employees. The company went IPO on 2023-03-30. The firm is engaged in the business of generating revenue through license fees by technology transfer of new drug candidates in pre-clinical and early clinical stages. The core new drug pipeline includes products such as GI-101 immuno-oncology and GI-301 allergy treatment.
See Also
What is GI Innovation Inc's Total Receivables?
Total Receivables
2B
KRW
Based on the financial report for Dec 31, 2023, GI Innovation Inc's Total Receivables amounts to 2B KRW.
What is GI Innovation Inc's Total Receivables growth rate?
Total Receivables CAGR 3Y
107%
Over the last year, the Total Receivables growth was -59%. The average annual Total Receivables growth rates for GI Innovation Inc have been 107% over the past three years .
You don't have any saved screeners yet
